阿托伐他汀对急性脑梗死患者血脂及预后的影响

Atorvastatin on blood lipids in patients with acute cerebral infarction and prognosis

目的：探讨阿托伐他汀对急性脑梗死患者血脂及预后的影响。方法入选的64例急性脑梗死患者均为2012年1月～2013年1月在我院住院治疗的患者，根据治疗方法不同分为治疗组和对照组各64例，两组均予抗血小板、改善脑循环、降压降糖等常规对症支持治疗，其中治疗组同时予以阿托伐他汀片20mg，每晚顿服，连用3个月。比较两组治疗后的总有效率及治疗前后两组患者的血浆总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）的变化情况。结果治疗组治疗3个月后，基本治愈20例，占31.25%；显著进步22例，占34.38%；进步18例，占28.13%；无变化3例，占4.69%；恶化1例，占1.57%；对照组治疗3个月后，基本治愈18例，占31.25%；显著进步19例，占34.38%；进步8例，占28.13%；无变化11例，占4.69%；恶化8例，占1.57%；治疗组的总有效率达93.75%，明显高于对照组，差异存在统计学意义（P＜0.05）。治疗3个月后，治疗组患者的TC、TG、LDL-C水平均较治疗后明显降低，HDL-C明显升高，而对照组患者治疗后TC、TG、HDL-C、LDL-C较治疗前比较，未见明显变化。且治疗组患者的TC、TG、LDL-C、HDL-C较对照组变化更显著，差异存在统计学意义（P＜0.05）。结论阿托伐他汀在急性脑梗死治疗过程中使用疗效确切，安全性好，能明显降低脑梗死患者的血脂水平，改善其预后，值得推广和应用。

Objective To investigate atorvastatin in patients with acute cerebral infarction lipids and prognosis. Methods 64 patients with acute cerebral infarction enrolled patients were in January 2012 to January 2013 in our hospital patients, according to the different treatment methods into treatment group and control group 64 cases, groups were treated antiplatelet improve cerebral circulation, blood pressure and other conventional symptomatic and supportive hypoglycemic efficacy in the treatment group are simultaneously atorvastatin tablets 20 mg, per night Dayton clothing, once every three months. Comparing two groups after treatment, the total effective two groups of patients before and after treatment plasma total cholesterol（TC）, triglyceride （TG）, low density lipoprotein （LDL-C）, high density lipoprotein （HDL-C） of changes. Results The treatment group after 3 months, basically cured 20 cases, accounting for 31.25%; significant progress in 22 cases, accounting for 34.38%; improvement in 18 cases, accounting for 28.13%; unchanged three cases, accounting for 4.69%; worsen one case, accounting 1.57%; control group after 3 months of treatment, the basic cure 18 cases, accounting for 31.25%; significant progress in 19 cases, accounting for 34.38%; progressive eight cases, accounting for 28.13%; no change in 11 cases, accounting for 4.69%; deterioration in 8 cases, accounting for 1.57%; treatment group, the total effective rate was 93.75%, significantly higher, there were significant differences（P 〈 0.05）.After 3 months of treatment, patients treated with TC,TG, LDL-C levels than significantly decreased after treatment, HDL-C was significantly higher in the control group after treatment TC, TG, HDL-C, LDL-C compared with before treatment, no significant change. And in patients treated with TC,TG, LDL-C, HDL-C compared with the control group more significantly, there was statistically significant difference（P 〈 0.05）. Conclusion Atorvastatin treatment of acute cerebral infarction efficacy, safety, and can significantly reduce lipid levels in patients with cerebral infarction and improve their prognosis, worthy of promotion and application .